Jeff Livingstone

CEO at Igia Pharmaceuticals

Speaker

Dr. Livingstone is currently CEO of Igia Pharmaceuticals, a pediatric rare disease company developing a novel therapy to address hypertrophic cardiomyopathy in infants and children with Noonan Syndrome or Noonan Syndrome with Multiple Lentigines. He is also CEO of Igia’s parent company LBR, a specialty clinical and regulatory development organization.

For nearly three decades Dr. Livingstone has been involved in both the technical and commercial aspects of entrepreneurial drug research and development. Dr. Livingstone received his PhD in Physical Biochemistry from the University of Wisconsin at Madison and his BS in Biochemistry from the University of Missouri at Columbia.